In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Medicine in St. Louis have found that the drug fluvoxamine seems to prevent some of the most serious complications of the illness and make hospitalization and the need for supplemental oxygen […]
New findings from researchers at Washington University School of Medicine in St. Louis suggest the eye’s cornea can resist infection from the novel coronavirus. Although the herpes simplex virus can infect the cornea and spread to other parts of the body in patients with compromised immune systems, and Zika virus has been found in tears […]
Rachel Presti, MD, PHD is the director of Washington University’s Infectious Diseases Clinical Research Unit and principal investigator for WashU’s COVID-19 vaccine trials. Sharon Frey, MD, is clinical director for SLU’s Center for Vaccine Development and principal investigator for SLU’s vaccine trials. Presti and Frey are coordinating so the two institutions can lead different vaccine […]
Lindsay to serve as co-chair for the Patient-Centered Outcomes Research Institute’s (PCORI) Advisory Panel on Rare Diseases, one of five multi-stakeholder advisory panels.
Phase 3 trial involves hospitalized patients with moderate to severe disease
Congratulations to ICTS investigator, Jonathan Bath, MD, assistant professor of surgery at the University of Missouri-Columbia School of Medicine and medical student Danielle Kinsey on their honorable mention in the NCATS Rare Diseases Are Not Rare 2020 Challenge .
Researchers at Washington University School of Medicine in St. Louis have received a pair of grants totaling $11.3 million to study genetic and environmental factors that contribute to developmental disabilities and to find new ways to improve the lives of children and adults affected by such disabilities.
Pieces of four antibodies (turquoise) attach to a protein from influenza B virus (gray) in the colorized cryo-electron microscopy reconstruction. Researchers at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai have identified two antibodies that protect mice against lethal infections of influenza B virus.
